---
title: "Biohaven 盘后下跌 20%，其针对 MDD（重度抑郁症）的 BHV-700 疗法研究结果没能达到主要目标。"
description: "Biohaven 盘后下跌 20%，其针对 MDD（重度抑郁症）的 BHV-700 疗法研究结果没能达到主要目标。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/270746105.md"
published_at: "2025-12-24T18:05:49.000Z"
---

# Biohaven 盘后下跌 20%，其针对 MDD（重度抑郁症）的 BHV-700 疗法研究结果没能达到主要目标。

Biohaven 盘后下跌 20%，其针对 MDD（重度抑郁症）的 BHV-700 疗法研究结果没能达到主要目标。

### Related Stocks

- [BHVN.US - Biohaven药业](https://longbridge.com/zh-CN/quote/BHVN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Biohaven highlights degrader platforms in new investor presentation | Biohaven Ltd. (BHVN) announced an investor presentation on January 12, 2026, detailing advancements in its drug developm | [Link](https://longbridge.com/zh-CN/news/272300228.md) |
| Biohaven reports Phase II BHV-7000 trial results for MDD | Biohaven announced Phase II trial results for BHV-7000 in MDD, showing no primary endpoint achievement but trends favori | [Link](https://longbridge.com/zh-CN/news/270844475.md) |
| China Grants Priority Review to Biogen and Eisai's Subcutaneous LEQEMBI Application | Biogen Inc. and Eisai Co., Ltd. have received Priority Review designation from China's National Medical Products Adminis | [Link](https://longbridge.com/zh-CN/news/275253143.md) |
| Biogen: Limited Near-Term Growth and Execution Risks Justify Neutral Hold Rating | Morgan Stanley analyst Terence Flynn maintained a Hold rating on Biogen with a price target of $190.00, citing limited n | [Link](https://longbridge.com/zh-CN/news/275233131.md) |
| Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance | Anixa Biosciences CEO Dr. Amit Kumar announced that 2026 will be a pivotal year for the company as it advances a breast  | [Link](https://longbridge.com/zh-CN/news/275508535.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。